Combinatorial In Situ Cancer Vaccines: Unlocking Broad and Enhanced Antitumor Responses
核心洞察
In situ cancer vaccination converts the tumor microenvironment into a personalized vaccine factory by harnessing the full antigenic repertoire of the tumor, enabling broad polyclonal T-cell responses.
Combining immunogenic cell death inducers with immunoadjuvants and immune checkpoint blockade overcomes immunosuppressive tumor microenvironment barriers and enhances systemic antitumor immunity.
Nanomedicine platforms address key delivery and retention challenges, enabling spatiotemporal control, multifunctional payload integration, and synergistic innate-adaptive immune crosstalk.
In situ cancer vaccination, also referred to as intratumoral immunotherapy (ITI), has emerged as a promising immunotherapeutic strategy that converts the tumor microenvironment into a personalized vaccine factory. Unlike conventional cancer vaccines that require exogenous delivery of tumor-associated antigens (TAAs) or neoantigens with immunoadjuvants, in situ vaccination elicits an immune response directly within the tumor site through intratumoral injection of immunoadjuvants such as toll-like receptor (TLR) agonists, proinflammatory cytokines, or oncolytic viruses. A defining advantage of this approach lies in its ability to harness the complete antigenic repertoire of the tumor, including shared TAAs, unique neoantigens, post-translationally modified epitopes, viral antigens, and oncofetal proteins, enabling the generation of broad and polyclonal cytotoxic T lymphocyte (CTL) responses that reduce the risk of antigen-loss variants and enhance targeting of heterogeneous tumor subclones.
Clinical Validation and Rationale
Recent clinical investigations have underscored the therapeutic potential of in situ vaccination. In a Phase I/II trial, 27% of patients with indolent lymphoma (搜索) achieved objective clinical responses at distant, noninjected tumor sites following intratumoral injection of the TLR9 (搜索) agonist PF-3512676 combined with low-dose radiotherapy, including one complete and three partial responses. Several responses were durable, lasting longer than prior therapies, and were associated with the induction of tumor-reactive memory CD8⁺ T cells. The oncolytic virus talimogene laherparepvec (T-VEC), which induces immunogenic cell death (ICD) and local immune activation, has demonstrated clinical benefit in melanoma (搜索), particularly when combined with immune checkpoint inhibitors. These findings support a strong rationale for integrating in situ vaccination with other immunotherapeutic modalities.
Immunogenic Cell Death as a Central Mechanism
ICD represents one of several mechanisms through which in situ vaccination initiates tumor immunity. Unlike tolerogenic cell death, ICD transforms dying tumor cells into a potent source of tumor-associated antigens and immune-activating signals by releasing damage-associated molecular patterns (DAMPs) such as calreticulin (CRT), high mobility group box 1 (HMGB1), and adenosine triphosphate (ATP). These DAMPs engage pattern recognition receptors (PRRs) on dendritic cells (DCs), promoting DC maturation, antigen cross-presentation, and T-cell priming.
Nonapoptotic forms of regulated cell death, including necroptosis, pyroptosis, and ferroptosis, are often highly immunogenic due to their ability to disrupt plasma membrane integrity and release DAMPs. Pyroptosis leads to pore formation and release of ATP, HMGB1, IL-1β, and IL-18, promoting DC recruitment and antigen presentation. Ferroptosis releases MDA and 4-HNE, which activate DCs and enhance cross-presentation while depleting M2 tumor-associated macrophages (TAMs). Each programmed cell death modality elicits a distinct repertoire of DAMPs, cytokines, and tumor-derived antigens that together influence DC activation, antigen cross-presentation, and T-cell priming.
Overcoming the Immunosuppressive Tumor Microenvironment
The efficacy of in situ cancer vaccination is constrained by the immunosuppressive tumor microenvironment (TME). Solid tumors create an immunosuppressive milieu characterized by immune checkpoint activation, suppressive immune cells including TAMs, myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), and inhibitory cytokines such as IL-10 and TGF-β. Hypoxia, induced by tumor growth and abnormal vasculature, reshapes the TME into a tolerogenic niche through stabilization of hypoxia-inducible factor 1α (HIF-1α), which limits oxidative phosphorylation and promotes glycolytic exhaustion in CD8⁺ T cells while impairing DC differentiation and antigen presentation.
Potent immunoadjuvants used in in situ cancer vaccines have been shown to downregulate MDSCs, M2-type TAMs, Tregs, and immature DCs while promoting infiltration and activation of CD8⁺ T cells, mature DCs, and M1 macrophages. This bidirectional remodeling converts the TME from a cold and tolerogenic niche into a hot and inflamed environment, restoring the APC–T-cell axis and enabling robust antitumor immunity.
Nanomedicine-Enabled Delivery Strategies
Nanomedicine has emerged as a versatile platform to overcome the intrinsic limitations of conventional in situ cancer vaccines. By integrating targeted delivery, spatiotemporal control, and multifunctional payload design, nanoplatforms significantly enhance antigen release, immune activation, and retention within the TME. In a study by Scheetz et al., synthetic high-density lipoprotein (sHDL) nanoparticles encapsulating docetaxel combined with the TLR9 (搜索) agonist CpG demonstrated superior antitumor efficacy in colon carcinoma models, with two of seven treated mice exhibiting complete tumor regression and no systemic toxicity observed.
Kuai et al. developed sHDL-mimicking nanodiscs delivering doxorubicin that exhibited hallmark ICD features, including approximately 3.5-fold increased CRT exposure and approximately 4-fold higher HMGB1 release compared to free doxorubicin. Combination therapy with anti–PD-1 (搜索) induced complete regression of established CT26 and MC38 colon carcinoma tumors in 80–88% of treated mice and generated durable immune memory, with mice resisting tumor rechallenge for over 60 days.
Duan et al. developed a self-assembled nanoscale coordination polymer core–shell nanoparticle (OxPt/DHA) for codelivery of oxaliplatin and dihydroartemisinin. In CT26 tumor-bearing mice, OxPt/DHA plus α-PD-L1 (搜索) achieved complete tumor regression in all treated mice within 40–50 days and prevented recurrence for at least 120 days. The combination markedly increased intratumoral CD8⁺ T-cell infiltration by approximately 4-fold compared to approximately 1-fold with OxPt/DHA alone.
Synergy with Immune Checkpoint Blockade
In situ cancer vaccination primes broad, patient-specific T-cell responses, but efficacy is often limited by immune checkpoints such as PD-1 (搜索)/PD-L1 (搜索) and CTLA-4 (搜索) that suppress CTL activity within the TME. Combining in situ cancer vaccination with immune checkpoint blockade (ICB) sustains effector T-cell function and transforms cold tumors into hot tumors with dense immune infiltration and proinflammatory signaling. Moon et al. engineered anti–PD-L1 peptide–conjugated prodrug nanoparticles that simultaneously deliver doxorubicin to induce ICD and block PD-L1–mediated immune suppression. In 4T1 murine breast tumor-bearing BALB/c mice, median survival improved to more than 30 days with PD-NPs, compared to approximately 20 days for free doxorubicin.
Multipathway ICD and Innate-Adaptive Crosstalk
Multipathway ICD strategies address limitations of conventional single-mechanism inducers by simultaneously activating complementary forms of regulated cell death. Hou et al. developed hydrazided hyaluronic acid–modified Zn–CuO₂ (HZCO) nanoparticles that induce PANoptosis by disrupting intracellular ion homeostasis, triggering concurrent activation of pyroptosis, apoptosis, and necroptosis. Intratumoral administration of HZCO markedly suppressed tumor growth in 4T1 breast cancer (搜索), CT26 colorectal, and B16F10 melanoma (搜索) models.
To boost innate-adaptive immune crosstalk, synthetic agonists targeting PRRs such as TLRs, NLRs, and STING (搜索) have been developed. Wang et al. developed dual-STING agonist micelles (D-SAM) that codeliver cGAMP and the polymer PC7A. A single intratumoral injection of D-SAM significantly suppressed tumor growth and extended median survival by up to 80% in B16F10, 4T1, and MC38 tumor models. Baljon et al. developed pH-responsive polymeric nanoparticles encapsulating MPLA, cGAMP, and tumor-specific peptides that expanded tumor-specific CD8⁺ T cells by over threefold, leading to complete tumor regression in more than 60% of mice.
Clinical Translation and Future Directions
Several ICD-inducing agents have reached clinical evaluation. Lurbinectedin (PM01183), a DNA-binding transcriptional inhibitor developed by PharmaMar (搜索), received FDA approval for treatment of adult patients with metastatic small-cell lung cancer (搜索) who have relapsed after first-line platinum-based chemotherapy. The drug activates the cGAS–STING (搜索) pathway, leading to interferon signaling, upregulation of proinflammatory chemokines, and increased expression of MHC-I and ICD-associated DAMPs. NK012, a polymeric micelle-based nanotherapeutic encapsulating SN-38, achieved a disease control rate of 56.6% and a median overall survival of 15.0 months in metastatic colorectal cancer (搜索) in a phase I/II clinical study.
Despite these advances, in situ cancer vaccines face key limitations including inconsistency of ICD induction, the immunosuppressive TME, and delivery and retention barriers. The dense extracellular matrix, elevated interstitial fluid pressure, and abnormal vasculature of solid tumors impede uniform distribution and durable retention of therapeutic components. Overcoming these challenges will require integrative approaches that address delivery constraints, circumvent tumor cell-intrinsic resistance, modulate immunosuppressive metabolism, and account for host genetic variability. Only by ensuring that tumor cell death is accompanied by effective innate activation and T-cell priming can in situ vaccination strategies reach their full therapeutic potential.